Prime Minister Justin Trudeau announced $175 million for a Vancouver biotech company, AbCellera Biologics Inc., which has identified antibodies that could be used to create treatments or a vaccine, in an May 3, 2020 story. (Photo by THE CANADIAN PRESS)

Prime Minister Justin Trudeau announced $175 million for a Vancouver biotech company, AbCellera Biologics Inc., which has identified antibodies that could be used to create treatments or a vaccine, in an May 3, 2020 story. (Photo by THE CANADIAN PRESS)

Vancouver biotech company discovering antibodies for COVID-19 treatment

Prime Minister Justin Trudeau announced $175 million federal funding for AbCellera

There may be another valuable shield in the fight against COVID-19, and the head of a Vancouver biotech firm says it could buy time as researchers race to develop a vaccine.

Carl Hansen, CEO of AbCellera Biologics Inc., said a drug built with antibodies could be used to protect vulnerable populations until a vaccine is more widely available.

The antibodies would give patients all the molecular material they need to fight the disease instead of depending on their bodies to develop their own as with a vaccine, giving them faster protection, he said.

“A prophylactic antibody could well be more effective than a vaccine,” he said.

On Sunday, Prime Minister Justin Trudeau announced $175 million federal funding for AbCellera to support its work in discovering those antibodies using a high-tech platform.

The funding also supports the company’s plans to build technology and manufacturing infrastructure for antibody therapies against future pandemic threats.

In partnership with pharmaceutical giant Eli Lilly, AbCellera is among a handful of companies on track for clinical trials this summer.

“There are many groups trying to rapidly develop vaccines for COVID-19 and vaccines are a very important part of the global response,” Hansen said.

“What we’re doing is different. What we’re doing is searching through an immune response that was generated from an actual infection and recovery in a patient and then finding that one antibody out of the literally millions that is best suited to stop the virus and that can be manufactured,” he said.

In 2012, Hansen said AbCellera recognized it could combine technologies from artificial intelligence, genomics, microfluidics and immunology to quickly search through natural immune systems to find antibodies that fight infection.

Two years ago, AbCellera began working with the Defense Advanced Research Projects Agency in the United States as part of a program to “radically accelerate” pandemic response, Hansen said. The company was working on simulations using its antibody-identifying technology when the COVID-19 pandemic struck.

“We quickly pivoted our efforts,” Hansen said.

Using blood samples from one of the first recovered COVID-19 patients in the United States on Feb. 25, AbCellera began screening millions of cells.

It narrowed down 500 unique human antibodies against the virus to a set of 24 that showed high promise of being therapeutic, he said.

“More recently we have further refined that set to a single antibody that is now being manufactured with the objective of having a first in-human trial start in July,” Hansen said.

What typically takes up to five years has been accelerated to less than four months, he said.

Vaccines and antibody-based prevention drugs work differently. With a vaccine, you inject a patient with a weakened virus or part of a virus to stimulate the immune system’s natural production of antibodies. With a prophylactic antibody, you insert the antibodies into the patient, Hansen said.

There are benefits and drawbacks. On one hand, prophylactics create more immediate protection because there’s no waiting period for the body to create its own antibodies. It’s also more broadly effective, because not all patients’ immune systems may be up to the task of producing their own antibodies.

On the other hand, a substantial number of antibodies must be administered to the patient in order to protect them.

“What that means is that the ability to manufacture hundreds of millions or even a billion doses of a vaccine is something well within the realm of possibility today. Making that many doses of antibodies is not,” he said.

That would mean giving the antibody to select groups of people at risk, such as health workers or the elderly, Hansen said.

The World Health Organization recommends that pharmacological treatment for COVID-19 should not be used outside of clinical trials.

On April 27, British Columbia’s COVID-19 therapeutics committee issued the same warning.

“There are no proven therapies for the prevention or treatment of COVID-19. All agents have the possibility of associated harm, and pharmaceutical supplies province-wide and nationally for many of the possible agents are severely limited,” it said.

For Hansen, research and development during the pandemic has not been business as usual.

“It’s not a race against our competitors nearly as much as it’s a race against the virus,” he said.

“What matters most is we get a therapy out there that works for patients and do so as quickly as possible.”

Amy Smart, The Canadian Press

Coronavirus

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

(File Photo)
COVID-19: District of Kent responds to provincial health restrictions

CRCC limits schedule, Municipal Hall offers alternate services for those unable to wear masks

Google Maps screenshot taken at 7:06 a.m.
Early-morning crash on Highway 1 has morning commuters in gridlock

Westbound crash occurred in Langley, west of 264th Street; left lane blocked

The Small Works display features work from local artists on wood panels. Panels are available at Ranger Station Art Gallery (File Photo)
Small Works submission deadline approaching

Ranger Station Art Gallery seeks local artists for upcoming display

Signs up at Hope Secondary School inform visitors that the school is a closed campus during the coronavirus pandemic. (Emelie Peacock/Hope Standard)
Second COVID-19 exposure at Hope Secondary School

Fraser Health website lists exposure on Nov. 11 and 12

New Chilliwack Chief Ray Fust.
Chilliwack Chief Ray Fust in the mix for Swiss U20 roster spot

Fust is hoping to make the team that will compete in the World Junior Hockey Championships

People wearing face masks to help curb the spread of COVID-19 cross a street in downtown Vancouver, on Sunday, November 22, 2020. The use of masks is mandatory in indoor public and retail spaces in the province. THE CANADIAN PRESS/Darryl Dyck
B.C. reports 17 COVID deaths, 1,933 new cases as hospitalizations surge over the weekend

There are 277 people in hospital, of whom 59 are in ICU or critical care

(Black Press Media files)
B.C. to test emergency alert system on cell phones, TVs, radios on Wednesday

The alert is part of a twice yearly test of the national Alert Ready system

Prime Minister Justin Trudeau speak to the media about the COVID-19 virus outside Rideau Cottage in Ottawa, Friday, Nov. 20, 2020. THE CANADIAN PRESS/Adrian Wyld
Canada’s inability to manufacture vaccines in-house will delay distribution: Trudeau

First doses of COVID-19 vaccine expected in first few months of 2021, prime minister says

Phillip Tallio was just 17 when he was convicted of murder in 1983 (file photo)
Miscarriage of justice before B.C. teen’s 1983 guilty plea in girl’s murder: lawyer

Tallio was 17 when he pleaded guilty to second-degree murder in the death of his 22-month-old cousin

Join Black Press Media and Do Some Good
Join Black Press Media and Do Some Good

Pay it Forward program supports local businesses in their community giving

Cannabis bought in British Columbia (Ashley Wadhwani/Black Press Media)
Is it time to start thinking about greener ways to package cannabis?

Packaging suppliers are still figuring eco-friendly and affordable packaging options that fit the mandates of Cannabis Regulations

This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. Pharmaceutical company AstraZeneca said Monday Nov. 23, 2020, that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals. (University of Oxford/John Cairns via AP)
VIDEO: How do the leading COVID vaccines differ? And what does that mean for Canada?

All three of the drug companies are incorporating novel techniques in developing their vaccines

An aerial shot of Cedar Valley Lodge this past August, LNG Canada’s newest accommodation for workers at the project site in Kitimat. This is where several employees are isolating after a COVID-19 outbreak was declared last Thursday (Nov. 19). (Photo courtesy of LNG Canada)
41 positive COVID-19 cases associated with the LNG Canada site outbreak in Kitimat

Thirty-four of the 41 cases remain active, according to Northern Health

7-year-old Mackenzie Hodge from Penticton sent a hand-written letter to premiere John Horgan asking if she’d be able to see her elf, Ralph under the new coronavirus restrictions. (John Horgan / Twitter)
Elf on the shelf an acceptable house guest, B.C. premier tells Penticton girl

A 7-year-old from Penticton penned a letter asking if she’d be allowed to see her elf this year

Most Read